Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma, Adult Epithelioid Sarcoma, Adult Extraskeletal Myxoid Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Peripheral Nerve Sheath Tumor, Adult Rhabdomyosarcoma, Adult Synovial Sarcoma, Adult Undifferentiated Pleomorphic Sarcoma, Malignant Adult Hemangiopericytoma, Recurrent Adult Soft Tissue Sarcoma, Sarcoma, Stage III Adult Soft Tissue Sarcoma AJCC v7, Stage IV Adult Soft Tissue Sarcoma AJCC v7
Conditions
Brief summary
This randomized phase II trial studies how well gemcitabine hydrochloride works with or without pazopanib hydrochloride in treating patients with refractory soft tissue sarcoma. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pazopanib hydrochloride may also stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether gemcitabine hydrochloride is more effective with or without pazopanib hydrochloride in treating patients with soft tissue sarcoma.
Detailed description
PRIMARY OBJECTIVES: I. To investigate whether treatment with gemcitabine (gemcitabine hydrochloride) plus pazopanib (pazopanib hydrochloride) improves the median progression-free survival (PFS) of patients with metastatic soft tissue sarcoma when compared to gemcitabine plus placebo. SECONDARY OBJECTIVES: I. To assess overall response in this population to gemcitabine plus pazopanib compared to gemcitabine plus placebo. II. To assess overall survival (OS) in this population to gemcitabine plus pazopanib compared to gemcitabine plus placebo. III. To investigate differences in treatment response in different histologic subgroups (liposarcoma vs. all other eligible soft tissue sarcoma subtypes). IV. To evaluate the safety and tolerability of the combination of gemcitabine plus pazopanib. V. To assess the progression-free survival and overall response in patients treated with single agent pazopanib following administration of gemcitabine in the cross-over portion of this study. VI. To collect specimens for an exploratory analysis of potential biomarkers that predict response in patients receiving combination therapy with gemcitabine plus pazopanib. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive gemcitabine hydrochloride intravenously (IV) over 30 minutes on days 1 and 8 and pazopanib hydrochloride orally (PO) on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and placebo PO on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may receive single-agent pazopanib hydrochloride PO daily. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. After the completion of study treatment, patients are followed up every 3 months.
Interventions
DRUGGemcitabine
Given IV
DRUGGemcitabine Hydrochloride
Given IV
OTHERLaboratory Biomarker Analysis
Correlative studies
DRUGPazopanib
Given PO
DRUGPazopanib Hydrochloride
Given PO
OTHERPlacebo Administration
Given PO
Sponsors
Novartis Pharmaceuticals
Oregon Health and Science University
OHSU Knight Cancer Institute
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Subjects must provide written informed consent prior to performance of study-specific procedures or assessments, and must be willing to comply with treatment and follow-up; procedures conducted as part of the subject's routine clinical management (e.g., blood count, imaging study) and obtained prior to signing of informed consent may be utilized for screening or baseline purposes provided these procedures are conducted as specified in the protocol * Histologically confirmed diagnosis of metastatic or unresectable soft tissue sarcoma, excluding gastrointestinal stromal tumors, Kaposi's sarcoma, Ewing's family of tumors, and embryonal or alveolar rhabdomyosarcoma * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 * Patients must have received at least one, but not more than three, systemic regimens for treatment of metastatic soft tissue sarcoma; patients must have had a prior anthracycline in the neoadjuvant, adjuvant, or metastatic setting unless medically inappropriate for the patient * Neoadjuvant or adjuvant therapy will not count towards prior treatment for metastatic disease, unless the patient relapsed within 2 years of completing such therapy. * Absolute neutrophil count (ANC) \>= 1.5 x 10\^9/L * Hemoglobin \>= 8 g/dL; subjects may not have had a transfusion within 7 days of screening assessment * Platelets \>= 100 x 10\^9/L * Prothrombin time (PT) or international normalized ratio (INR) =\< 1.2 x upper limit of normal (ULN); subjects receiving anticoagulation therapy are eligible if their INR is stable and within the recommended range for the desired level of anticoagulation * Activated partial thromboplastin time (aPTT) =\< 1.2 x ULN * Total bilirubin =\< 1.5 x ULN * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =\< 2.5 x ULN; concomitant elevations in bilirubin and AST/ALT above 1.0 x ULN (upper limit of normal) are not permitted * Serum creatinine =\< 1.5 mg/dL (133 umol/L) * Or, if \> 1.5 mg/dL: calculated creatinine clearance (ClCR) \>= 30 mL/min * Urine protein to creatinine ratio (UPC) \< 1; if UPC \>= 1, then a 24-hour urine protein must be assessed; subjects must have a 24-hour urine protein value \< 1 g to be eligible; use of urine dipstick for renal function assessment is not acceptable * Or 24-hour urine protein \< 1 g * A female is eligible to enter and participate in this study if she is of: * Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who has had: * A hysterectomy * A bilateral oophorectomy (ovariectomy) * A bilateral tubal ligation * Is post-menopausal * Subjects not using hormone replacement therapy (HRT) must have experienced total cessation of menses for \>= 1 year and be greater than 45 years in age, OR, in questionable cases, have a follicle stimulating hormone (FSH) value \> 40 mIU/mL and an estradiol value \< 40 pg/mL (\< 140 pmol/L) * Subjects using HRT must have experienced total cessation of menses for \>= 1 year and be greater than 45 years of age OR have had documented evidence of menopause based on FSH and estradiol concentrations prior to initiation of HRT * Childbearing potential, including any female who has had a negative serum pregnancy test within 7 days prior to the first dose of study treatment, preferably as close to the first dose as possible, and agrees to use adequate contraception; defined as follows: * Complete abstinence from sexual intercourse for 14 days before exposure to investigational product, through the dosing period, and for at least 21 days after the last dose of investigational product * Oral contraceptive, either combined or progesterone alone * Injectable progesterone * Implants of levonorgestrel * Estrogenic vaginal ring * Percutaneous contraceptive patches * Intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1% per year * Male partner sterilization (vasectomy with documentation of azoospermia) prior to the female subject's entry into the study, and this male is the sole partner for that subject * Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/film/cream/suppository) * Female subjects who are lactating should discontinue nursing prior to the first dose of study drug and should refrain from nursing throughout the treatment period and for 14 days following the last dose of study drug
Exclusion criteria
* Prior malignancy; note: subjects who have had another malignancy and have been disease-free for \> 3 years, or subjects with a history of completely resected non-melanomatous skin carcinoma, successfully treated in situ carcinoma, or successfully treated superficial bladder cancer are eligible. * History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, except for individuals who have previously-treated CNS metastases, are asymptomatic, and have had no requirement for steroids or anti-seizure medication for 6 months prior to first dose of study drug; screening with CNS imaging studies (computed tomography \[CT\] or magnetic resonance imaging \[MRI\]) is required only if clinically indicated or if the subject has a history of CNS metastases * Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding including, but not limited to: * Active peptic ulcer disease * Known intraluminal metastatic lesion/s with risk of bleeding * Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other gastrointestinal conditions with increased risk of perforation * History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days prior to beginning study treatment * Clinically significant gastrointestinal abnormalities that may affect absorption of investigational product including, but not limited to: * Malabsorption syndrome * Major resection of the stomach or small bowel * Presence of uncontrolled infection * Corrected QT interval (QTc) \> 480 msecs using Bazett's formula * History of any one or more of the following cardiovascular conditions within the past 6 months: * Cardiac angioplasty or stenting * Myocardial infarction * Unstable angina * Coronary artery bypass graft surgery * Symptomatic peripheral vascular disease * Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA) * Poorly controlled hypertension (defined as systolic blood pressure \[SBP\] of \>= 140 mmHg or diastolic blood pressure \[DBP\] of \>= 90mmHg); note: initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry; following antihypertensive medication initiation or adjustment, blood pressure (BP) must be re-assessed three times at approximately 2-minute intervals; at least 24 hours must have elapsed between anti-hypertensive medication initiation or adjustment and BP measurement; these three values should be averaged to obtain the mean diastolic blood pressure and the mean systolic blood pressure; the mean SBP/DBP ratio must be \< 140/90 mmHg * History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months; note: subjects with recent DVT who have been treated with therapeutic anti-coagulating agents for at least 6 weeks are eligible * Prior major surgery or trauma within 28 days prior to first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer (procedures such as catheter placement not considered to be major) * Evidence of active bleeding or bleeding diathesis * Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that increase the risk of pulmonary hemorrhage * Hemoptysis in excess of 2.5 mL (or one half teaspoon) within 8 weeks of first dose of study drug * Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures * Unable or unwilling to discontinue use of prohibited medications for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of the study; administration of any non-oncologic investigational drug within 30 days or 5 half-lives whichever is longer prior to receiving the first dose of study treatment * Treatment with any of the following anti-cancer therapies: * Radiation therapy, surgery or tumor embolization within 14 days prior to the first dose of pazopanib OR * Chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within 14 days (or 28 days in the case of monoclonal antibody therapy) prior to the first dose of pazopanib. * Any prior treatment with pazopanib. * Prior treatment with vascular endothelial growth factor (VEGF) or vascular endothelial growth factor receptor (VEGFR)-targeting agents other than pazopanib (eg. sorafenib, sunitinib, and bevacizumab) in the metastatic setting. Prior use of such agents in the neoadjuvant or adjuvant setting is permitted. * Any prior treatment with gemcitabine for metastatic disease. Prior use of gemcitabine in the neoadjuvant or adjuvant setting is permitted. * Any ongoing toxicity from prior anti-cancer therapy that is \> grade 1 and/or that is progressing in severity, except alopecia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) | Calculated as the time from randomization to the first documented progression or death, whichever occurs first, or until time of last contact if no progression or death occurred, assessed up to 3 years | Compared using a one-sided Gehan-Wilcoxon test stratified by sarcoma subtype. Kaplan-Meier estimates for each treatment arm will be presented with the estimated hazard ratios and their associated confidence intervals. Progression is defined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.0 as at least a 20% increase in the sum of the longest diameters of target lesions (taking as reference the smallest sum on study) with an absolute increase of at least 5 mm (target lesions), or measurable increase in non-target lesions (unequivocal progression), or appearance of one or more new lesions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival (PFS) for a Sub-group of Patients Treated With Open-label Pazopanib Hydrochloride Following Administration of Gemcitabine Hydrochloride in the Cross-over Portion of This Study | Calculated as the time from receiving open-labeled pazopanib hydrochloride to the next documented progression or death whichever occurs first, assessed up to 3 years | Participants who progress during treatment and are found to be part of the gemcitabine+placebo arm after unblinding are eligible to receive open-label pazopanib with gemcitabine. This is the crossover population. Statistical analysis is exploratory and requires sufficient crossover participants to assess Kaplan-Meier estimated hazard ratio and associated 95% confidence interval. This represents the participants second progression. In both cases progression is defined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.0 as at least a 20% increase in the sum of the longest diameters of target lesions with an absolute increase of at least 5 mm (target lesions), or measurable increase in non-target lesions (unequivocal progression), or appearance of one or more new lesions. First progression uses the smallest sum on study as a reference; progression for the crossover population uses first progression measurements as the reference. |
| Percentage of Participants Achieving Best Overall Objective Response (CR+PR) | Best overall objective response recorded from the start of treatment until disease progression/recurrence assessed up to 3 years | Response is evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, where RECIST combines assessments for target, non-target and presence of new lesions. Best Overall Objective Response is the sum of all CR+PR divided by all randomized participants, where the strongest recorded response is used for the evaluation (CR\>PR\>SD\>PD). Objective response (CR+PR) requires at least a 30% decrease in the sum of the largest diameter target lesions (with respective to the baseline sum); disappearance of all or persistence of one or more non-target lesions, maintenance of tumor marker levels above normal limits, and no new lesions. Estimated odds ratio of best overall objective response are reported with 95% confidence interval for the two histologic sarcoma subgroups (liposarcoma vs all other eligible soft tissue sarcoma subtypes). One-sided proportions test is used to determine whether best overall objective response is greater for the gemcitabine plus pazopanib group. |
| Overall Survival | From randomization to death due to any cause, or until last patient contact if the patient did not die, assessed up to 3 years | Two treatment arms will be compared using a one-sided log-rank test stratified by sarcoma subtype and study site. Kaplan-Meier estimates and the survival curves for each treatment arm will be presented with the estimated hazard ratios and their associated confidence interval. |
Countries
United States
Participant flow
Pre-assignment details
Double-blinded randomization (1:1) was stratified by subtypes of sarcoma (liposarcoma vs. all other eligible soft tissue sarcoma subtypes). Patients were randomized to either experimental arm or placebo arm prior to starting treatment. Those who discontinued treatment on the placebo arm due to disease progression were eligible for treatment with open-label pazopanib (unblinded, cross-over treatment); those who developed disease progression on the Experimental arm (pazopanib arm) were not.
Participants by arm
| Arm | Count |
|---|---|
| Gemcitabine Hydrochloride Plus Pazopanib Hydrochloride Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and pazopanib hydrochloride PO on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Gemcitabine: Given IV
Gemcitabine Hydrochloride: Given IV
Laboratory Biomarker Analysis: Correlative studies
Pazopanib: Given PO
Pazopanib Hydrochloride: Given PO | 29 |
| Gemcitabine Hydrochloride Plus Placebo Patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 and placebo PO on days 1-21. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who experience disease progression may receive single-agent pazopanib hydrochloride PO daily. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Gemcitabine: Given IV
Gemcitabine Hydrochloride: Given IV
Laboratory Biomarker Analysis: Correlative studies
Pazopanib: Given PO
Pazopanib Hydrochloride: Given PO
Placebo Administration: Given PO | 25 |
| Total | 54 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 6 | 1 |
| Overall Study | Death | 2 | 0 |
| Overall Study | Physician Decision | 2 | 1 |
| Overall Study | Protocol-defined delay > 3 weeks | 3 | 0 |
| Overall Study | Withdrawal by Subject | 1 | 0 |
Baseline characteristics
| Characteristic | Gemcitabine Hydrochloride Plus Pazopanib Hydrochloride | Gemcitabine Hydrochloride Plus Placebo | Total |
|---|---|---|---|
| Age, Continuous | 63 years | 56 years | 60 years |
| Histology Leiomyosarcoma (LMS) | 9 Participants | 5 Participants | 14 Participants |
| Histology Liposarcoma | 9 Participants | 7 Participants | 16 Participants |
| Histology Other Sarcoma(s) | 5 Participants | 5 Participants | 10 Participants |
| Histology Synovial Sarcoma | 3 Participants | 3 Participants | 6 Participants |
| Histology Undifferentiated Pleomorphic Sarcoma (UPS) | 3 Participants | 5 Participants | 8 Participants |
| Number Prior Treatments | 1 Treatments | 1 Treatments | 1 Treatments |
| Race/Ethnicity, Customized Asian | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Unknown/Not Reported | 3 Participants | 1 Participants | 4 Participants |
| Race/Ethnicity, Customized White | 25 Participants | 24 Participants | 49 Participants |
| Sex: Female, Male Female | 14 Participants | 16 Participants | 30 Participants |
| Sex: Female, Male Male | 15 Participants | 9 Participants | 24 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 23 / 29 | 10 / 11 | 11 / 14 |
| other Total, other adverse events | 25 / 29 | 14 / 25 | 9 / 14 |
| serious Total, serious adverse events | 8 / 29 | 6 / 25 | 5 / 14 |
Outcome results
Primary
Progression-free Survival (PFS)
Compared using a one-sided Gehan-Wilcoxon test stratified by sarcoma subtype. Kaplan-Meier estimates for each treatment arm will be presented with the estimated hazard ratios and their associated confidence intervals. Progression is defined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.0 as at least a 20% increase in the sum of the longest diameters of target lesions (taking as reference the smallest sum on study) with an absolute increase of at least 5 mm (target lesions), or measurable increase in non-target lesions (unequivocal progression), or appearance of one or more new lesions.
Time frame: Calculated as the time from randomization to the first documented progression or death, whichever occurs first, or until time of last contact if no progression or death occurred, assessed up to 3 years
Population: All randomized participants
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Gemcitabine Hydrochloride Plus Pazopanib Hydrochloride | Progression-free Survival (PFS) | Other Sarcoma | 4.4 months |
| Gemcitabine Hydrochloride Plus Pazopanib Hydrochloride | Progression-free Survival (PFS) | All randomized | 4.5 months |
| Gemcitabine Hydrochloride Plus Pazopanib Hydrochloride | Progression-free Survival (PFS) | Liposarcoma | 8.9 months |
| Gemcitabine Hydrochloride Plus Placebo | Progression-free Survival (PFS) | All randomized | 1.6 months |
| Gemcitabine Hydrochloride Plus Placebo | Progression-free Survival (PFS) | Liposarcoma | 1.5 months |
| Gemcitabine Hydrochloride Plus Placebo | Progression-free Survival (PFS) | Other Sarcoma | 2.2 months |
Comparison: Statistical results are for the full randomized population (n = 54). The study was originally designed with overall one-sided alpha of 5%, where a total of 73 patients (36 in the gemcitabine + placebo arm, and 37 in the gemcitabine + pazopanib arm) were required to achieve 80% power to detect a 2.5 month increase in median PFS (a hazard ratio of 0.55) between the two treatment arms. Study was closed early by the sponsor due to slow accrual and funds and thus was under powered.p-value: 0.017Gehan-Wilcoxon
Comparison: Comparison between the two arms for the liposarcoma subgroupp-value: 0.195Gehan-Wilcoxon
Comparison: Statistical results are for the 'other' sarcoma subgroup (n = 38)p-value: 0.079Gehan-Wilcoxon
Secondary
Overall Survival
Two treatment arms will be compared using a one-sided log-rank test stratified by sarcoma subtype and study site. Kaplan-Meier estimates and the survival curves for each treatment arm will be presented with the estimated hazard ratios and their associated confidence interval.
Time frame: From randomization to death due to any cause, or until last patient contact if the patient did not die, assessed up to 3 years
Population: All randomized participants
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Gemcitabine Hydrochloride Plus Pazopanib Hydrochloride | Overall Survival | All Randomized | 11.0 months |
| Gemcitabine Hydrochloride Plus Pazopanib Hydrochloride | Overall Survival | Liposarcoma participants | 20.5 months |
| Gemcitabine Hydrochloride Plus Pazopanib Hydrochloride | Overall Survival | Other Sarcoma participants | 10.2 months |
| Gemcitabine Hydrochloride Plus Placebo | Overall Survival | Other Sarcoma participants | 17.7 months |
| Gemcitabine Hydrochloride Plus Placebo | Overall Survival | All Randomized | 15.6 months |
| Gemcitabine Hydrochloride Plus Placebo | Overall Survival | Liposarcoma participants | 5.7 months |
Comparison: Overall survival estimated among all randomized participants (n = 54)p-value: 0.481Gehan-Wilcoxon
Comparison: Overall survival compared between the two arms for the liposarcoma subgroup (n = 16)p-value: 0.353Gehan-Wilcoxon
Comparison: Overall survival comparison between the two treatment arms for the other sarcoma group (n = 38)p-value: 0.408Gehan-Wilcoxon
Secondary
Percentage of Participants Achieving Best Overall Objective Response (CR+PR)
Response is evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, where RECIST combines assessments for target, non-target and presence of new lesions. Best Overall Objective Response is the sum of all CR+PR divided by all randomized participants, where the strongest recorded response is used for the evaluation (CR\>PR\>SD\>PD). Objective response (CR+PR) requires at least a 30% decrease in the sum of the largest diameter target lesions (with respective to the baseline sum); disappearance of all or persistence of one or more non-target lesions, maintenance of tumor marker levels above normal limits, and no new lesions. Estimated odds ratio of best overall objective response are reported with 95% confidence interval for the two histologic sarcoma subgroups (liposarcoma vs all other eligible soft tissue sarcoma subtypes). One-sided proportions test is used to determine whether best overall objective response is greater for the gemcitabine plus pazopanib group.
Time frame: Best overall objective response recorded from the start of treatment until disease progression/recurrence assessed up to 3 years
Population: All randomized participants.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Gemcitabine Hydrochloride Plus Pazopanib Hydrochloride | Percentage of Participants Achieving Best Overall Objective Response (CR+PR) | All randomized participants | 6.9 percentage of participants |
| Gemcitabine Hydrochloride Plus Pazopanib Hydrochloride | Percentage of Participants Achieving Best Overall Objective Response (CR+PR) | Liposarcoma participants | 22.2 percentage of participants |
| Gemcitabine Hydrochloride Plus Pazopanib Hydrochloride | Percentage of Participants Achieving Best Overall Objective Response (CR+PR) | Other sarcoma participants | 0 percentage of participants |
| Gemcitabine Hydrochloride Plus Placebo | Percentage of Participants Achieving Best Overall Objective Response (CR+PR) | All randomized participants | 8.0 percentage of participants |
| Gemcitabine Hydrochloride Plus Placebo | Percentage of Participants Achieving Best Overall Objective Response (CR+PR) | Liposarcoma participants | 0 percentage of participants |
| Gemcitabine Hydrochloride Plus Placebo | Percentage of Participants Achieving Best Overall Objective Response (CR+PR) | Other sarcoma participants | 11.1 percentage of participants |
Comparison: Statistical results are for the full randomized population (n = 54). The study tests whether gemcitabine plus pazopanib is superior to gemcitabine plus placebo (one-sided proportion test with Yate's continuity correction)p-value: 0.5One-sided Proportions Test
Comparison: Statistical results are for the Liposarcoma group (n = 16). The study tests whether gemcitabine plus pazopanib is superior to gemcitabine plus placebo (one-sided proportion test with Yate's continuity correction). Analysis was not powered for the secondary endpoints. Given the study closed early due to slow enrollment we do not anticipate detecting a statistical difference between the groups.p-value: 0.3One-sided Proportion Test
Comparison: Statistical results are for the Other Sarcoma group (n = 38). The study tests whether gemcitabine plus pazopanib is superior to gemcitabine plus placebo (one-sided proportion test with Yate's continuity correction). Analysis was not powered for secondary endpoints. Given the study closed early due to slow enrollment, we do not anticipate detecting a statistical difference between the two groups.p-value: 0.8One-sided Proportion Test
Secondary
Progression-free Survival (PFS) for a Sub-group of Patients Treated With Open-label Pazopanib Hydrochloride Following Administration of Gemcitabine Hydrochloride in the Cross-over Portion of This Study
Participants who progress during treatment and are found to be part of the gemcitabine+placebo arm after unblinding are eligible to receive open-label pazopanib with gemcitabine. This is the crossover population. Statistical analysis is exploratory and requires sufficient crossover participants to assess Kaplan-Meier estimated hazard ratio and associated 95% confidence interval. This represents the participants second progression. In both cases progression is defined using Response Evaluation Criteria in Solid Tumors (RECIST) v1.0 as at least a 20% increase in the sum of the longest diameters of target lesions with an absolute increase of at least 5 mm (target lesions), or measurable increase in non-target lesions (unequivocal progression), or appearance of one or more new lesions. First progression uses the smallest sum on study as a reference; progression for the crossover population uses first progression measurements as the reference.
Time frame: Calculated as the time from receiving open-labeled pazopanib hydrochloride to the next documented progression or death whichever occurs first, assessed up to 3 years
Population: Participants randomized to the gemcitabine + placebo arm who progressed and elected to receive gemcitibine + open-label pazopanib
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Gemcitabine Hydrochloride Plus Pazopanib Hydrochloride | Progression-free Survival (PFS) for a Sub-group of Patients Treated With Open-label Pazopanib Hydrochloride Following Administration of Gemcitabine Hydrochloride in the Cross-over Portion of This Study | 3.0 months |